To date, no cardiovascular model has been able to shed light on how and why cardiac congenital disorders start in the human embryo. Researchers from the Institute of Molecular Biotechnology (IMBA) in Vienna have been able to recapitulate cardiogenesis in multi-chamber cardioids, sort of interacting heart chambers intended to dissect how genetic and environmental factors impact human heart development. Read More
Researchers from Medical University of South Carolina aimed to evaluate the potential of secreted frizzled-related protein 2 (SFRP2) as a promising novel target for breast cancer using a newly developed humanized monoclonal antibody to SFRP2 (hSFRP2 MAb) in models of this disease. Read More
Scinai Immunotherapeutics Ltd. has released promising preclinical results of its innovative anti‑IL‑17 VHH antibody (NanoAb) as a local treatment for mild to moderate plaque psoriasis. Read More
Vanqua Bio Inc. announced that its development candidate VQ-101, a best-in-class brain-penetrant small-molecule allosteric activator of glucocerebrosidase (GCase), will enter clinical development in the first quarter of next year, with an initial indication in Parkinson’s disease. Read More
The inhibition of cyclin-dependent kinase 4 (CDK4) and CDK6 is a useful strategy to treat hormone receptor (HR)+/HER2+ breast cancer, but patients may develop resistance through different mechanisms. As reported at the recent San Antonio Breast Cancer Symposium, researchers from Biotheryx Inc. have synthesized a new CDK4/6 degrader – BTX-9341 – to address the problem of therapeutic resistance in breast cancer. Read More
The emergence of Staphylococcus aureus strains resistant to almost all approved antibiotics in the clinic poses an urgent public health concern. Thus, new antibiotics exploiting alternative antibacterial mechanisms or molecular structures are critically needed to address the long-term threat of multidrug-resistant S. aureus, particularly methicillin-resistant S. aureus (MRSA). Read More
Astrazeneca AB has disclosed 17-β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17-β-HSD 13) inhibitors reported to be useful for the treatment of alcoholic liver disease, liver fibrosis, cirrhosis, hepatic steatosis, liver inflammation, hepatitis C virus infection and liver cancer. Read More
Gigagen Inc., a subsidiary of Grifols SA, has received clearance from the FDA of its IND application to conduct a phase I trial of GIGA-564 for the treatment of solid tumors. Read More
Shinobi Therapeutics Inc. has closed a $51 million series A financing. The company is developing a new class of off-the-shelf immune evasive iPSC-derived cell therapies. Read More
Repare Therapeutics Inc. has identified membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer. Read More
Rheumatoid arthritis (RA) is a systemic autoimmune disorder where Bruton tyrosine kinase (BTK) and Janus kinase 3 (JAK3) are among the most relevant signaling pathways involved. Read More
Amyotrophic lateral sclerosis (ALS) is associated with loss of synaptic connectivity at the neuromuscular junction (NMJ) and loss of motor neurons. Read More
Merck Sharp & Dohme LLC has divulged compounds acting as lipid A export ATP-binding/permease protein (MsbA) inhibitors reported to be useful for the treatment of gram-negative (multidrug-resistant) bacterial infections. Read More
Eli Lilly & Co. has described compounds acting as angiotensin AT2 receptor (AGTR2) antagonists reported to be useful for the treatment of pain. Read More
Immuneering Corp. has obtained FDA clearance of its IND application for IMM-6-415, an oral, twice-daily small molecule in development for the treatment of advanced RAF or RAS mutant solid tumors. Read More
Are you trying to stay on top of developments in CAR T therapies? Drug resistance? Emerging compounds? Updates from certain regulatory agencies? Want to be the first to learn about new biomarkers or business deals? You can still find these articles in the daily BioWorld e-newsletters or on the website, but if you’re laser-focused on a specific topic, we have a way to highlight the news you need as it happens, whether we’ve published a full-length feature story or a brief update. You asked and we listened. Now, in addition to the daily news lineup, you can create topic alerts to be delivered directly to your inbox or via an RSS reader. It’s easy to set up. Instructions can be found here: https://www.bioworld.com/featured-feeds. Happy holidays! Read More